Introduction
Severe combined immunodeficiency (SCID) is a heterogeneous group of rare autosomic recessive disorders occurring in 1:75 000 to 1:100 000 births. The common characteristic of these pathologies is the absence of T cells associated with an impaired function of B lymphocytes leading to death within the first year of life in the absence of treatment 1, 2 .
Currently, the treatment of choice is allogenic hematopoietic stem cell transplantation (HSCT) with a survival rate approximating 90% when an HLA-genoidentical donor is available 3 . In most cases, haploidentical donors or unrelated donors are the only source of allogenic hematopoietic stem cells and in this case, the survival rate ranges from 60 to 75%. Within the SCID subsets, the T-B-NK+ group has a poorer prognosis, especially when a partially compatible donor is used (with a survival rate close to 36%). Of note, this subgroup of mismatched transplanted patients presents a number of long-term complications due to a frequent persistence of B cell deficiency and a long-term decline in T-cell functions related to the absence of donor stem cell engraftment 4 . The slow kinetics of the T lymphocyte development also accounts for many lethal infections observed in the first 6 months after HSCT. These limitations justify the search for an alternative strategy in order to improve the prognosis of SCID. Transfer of a normal copy of the mutated gene which causes the SCID disease to early hematopoietic progenitors has largely been considered and this therapeutical approach has provided efficient long term correction in two human SCID diseases 5, 6, 7, 8 as well as in various immunodeficient mouse models 9, 10, 11, 12 .
The T-B-NK+ group of SCID disease represents 20-30% of the all SCID forms. Within this subset, mutations in one of the two Recombination Activating Genes: RAG-1 or RAG-2 13, 14 accounts for half of the cases. Both RAG-1 and RAG-2 proteins play a key role in the initiation of the V(D)J recombination step, crucial for the formation of the antigen receptor at only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From the surface of T and B lymphocytes 15, 16 . The simultaneous expression of RAG-1 and RAG-2 is required during the early stages of T and B lymphocyte maturation and in the absence of one of the two proteins, lymphoid differentiation is blocked at the pro-B and triple negative pre-T stages 17 . Of note, in humans, hypomorphic mutations of RAG proteins can lead to a leaky phenotype, the Omenn syndrome, characterized by the presence of a few autoreactive T cells clones 18 . RAG-1 and RAG-2 deficient mice (RAG-1-/-and RAG-2-/-, respectively)
exhibit an identical phenotype 19, 20 to the one observed in RAG deficient patients with null mutations. Therefore, these animals represent a good model to test the efficiency and toxicity of RAG-1 gene therapy approach.
We have previously demonstrated that RAG-2 deficiency could be long-term corrected following retroviral transfer of the human RAG-2 gene in the HSC of RAG-2-/-mice 11 . Using the same strategy, the human RAG-1 (hRAG-1) transgene was cloned in a Moloney leukemia virus (MLV) vector used to transduce bone marrow progenitors of RAG-1-/-deficient mice. T and B cell differentiation was restored in all the lymphoid organs for more than one year after transplantation provided that the transgene copy number per cell was high enough. Of note, such a high provirus copy number lead to the occurrence of one leukemic event. Together with the observed clinical complications in the γc deficiency trial 21 these results indicate that alternative transduction methods, such as LTR-inactivated retroviral vectors should be used for this therapeutical approach.
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Materials and methods

Mice
Four to 6 week old C57BL/10 wild type mice and C57BL/10 RAG-1-deficient mice were obtained from Charles River laboratories (l'Arbresle, France). The animals were maintained in a specific pathogen-free animal facility. All experiments and procedures were performed in 
Retroviral supernatant production
MFG-RAG1 vector was obtained by a Sal-1/Nco1 ligation of the human RAG-1 cDNA product into the MFGΒ2 plasmid which has been described elsewhere 22 . Retroviral supernatant was produced in Stemspan medium (Stem Cell Technologies, VC, Canada)
supplemented with 10% fetal bovine serum (FBS, Stem Cell Technologies). Briefly, ecotropic phoenix producer cells line were transfected following a calcium-phosphate protocol as previously described 11 . After 48 hours, the supernatant was collected and concentrated onto vivaspin concentrator tubes (Vivascience, Hannover, Germany). Virus titration was performed on 3T3 cell lines, estimated at 6x10 6 i.p./ml and used at a multiplicity of infection of 3. The detection of Replication Competent Retrovirus (RCR) in the retroviral supernatant batches was performed by Texcell (Paris, France) 23 . No RCR were detected.
Transduction of bone marrow cells
Bone marrow cells were flushed from both tibias and femora of donor mice and treated with a were purified using an anti-PE magnetic selection kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Sca-1+ cells were cultured for 24 hours in Stemspan medium (Stem Cell Technologies) supplemented with 5% FBS (Stem Cell Technologies) and the following recombinant cytokines: murine Stem Cell Factor (mSCF) 100 ng/ml (Abcys, Paris, France), human FMS-like tyrosine kinase 3-Ligand (hFlt3-L) 100 ng/ml, and human Megakaryocyte Growth and Development Factor (hMGDF) 100 ng/ml (Amgen, Thousand Oaks, CA), mIL-6 50 ng/ml (Abcys), mIL-11 10 ng/ml (R&D, Minneapolis, MN). Cells were seeded at 1x10 6 cells/ml in flat-bottomed P96 wells coated with 50 µg/ml recombinant human fibronectin fragment (RetroNectin CH-296; Takara Biomedicals, Shiga, Japan). Three transduction cycles were performed at 24-hour intervals by replacing the medium with retroviral supernatant supplemented with the same cytokines and protamine sulfate (4 µg/ml) (Choay, Gentilly, France). One million cells were injected intravenously to RAG-1-deficient mouse previously irradiated at 300 or 800 cGy using a 137 Cs irradiator. The control group was obtained by transplanting 1x10 6 wild type C57BL/10 cells previously cultured with the protocol described above. Mice treated with MFG-RAG-1 were sacrified 4 to 6 months after transplantation and secondary grafts were performed as follows : bone marrow cells were collected, treated with an NH4Cl solution, and a total of 5x10 6 cells/ml were injected intravenously to 300 or 800 cGy irradiated RAG-1-/-recipients.
Flow cytometry analysis
Flow cytometry analyzes were performed on cells obtained from blood, thymus, bone marrow, spleen, and lymph nodes. Cells were counted with trypan blue and stained with the following rat anti-mouse monoclonal antibodies (Becton Dickinson (BD) Biosciences (Applied Biosystems, Foster City, CA). PCR products were then subjected to run-off reactions by using nested fluorescents primers specific for the Cβ or Cα segment. Labelled products were resolved on an automated 373A sequencer (Perkin Elmer, Foster City, CA).
The fluorescence intensity of each band was recorded and analyzed using the Immunoscope software 24 , 25 . Reverse transcription (RT) was performed in a 20 μl final volume and the sample was incubated at 42°C for 60 min. To account for variations due to RNA extraction and the RT reaction, the measured level of hRAG-1 transgene mRNA was normalized against an endogenous RNA control, PO mRNA, an acidic ribosomal phosphoprotein ubiquitly expressed in all murine cells 26 . Ratios were calculated by comparing the hRAG-1 mRNA expression levels (hRAG-1/PO) in the tested samples with murine RAG-1 expression levels in the thymus of wild type C57BL/10 mice (mRAG-1/PO). The hRAG-1 transcript expression value was calculated as a percentage of the reference mRAG-1/PO ratio in the thymus.
Serum immunoglobulin quantification and antibody response to a T-cell-dependent antigen
The primers and probes sequences used are shown in the 
LAM-PCR analysis
An integration site restriction fragment length display was obtained by linear amplificationmediated PCR (LAM-PCR), consisting of repeated primer extension, second strand synthesis, restriction digest, cassette ligation and exponential amplification as described previously 27 .
LAM-PCR was performed on DNA isolated from spleen, bone-marrow or liver cells and the 
Results
Immune reconstitution following ex-vivo RAG-1 gene transfer
Six months following gene transfer, T cell development was analyzed in the RAG-1 transduced mice (RAG1-TM, n=9) as well as in RAG-1-/-control mice that received congenic wild type bone-marrow cells (WT-CTRL, n=8). In the recipient mice irradiated with a 8Gy dose (n=4), thymocyte counts and thymic reconstitution feature are undistinguishable from WT-CTRL mice (Fig 1, Table 1 ). In the 3Gy irradiated group (n=5), overall thymocyte counts were more variable (from 1x10 5 cells to 8x10 6 cells) and lower than the thymocyte counts observed in the 8Gy irradiated group (p< 5%). Of note, CD4 + CD8 + double positive cells (DP)
were found in only 2/5 recipients although mature single positive (SP) thymocytes
were detected in all cases. In both RAG1-TM and WT-CTRL groups, the presence of DP cells was associated with a normal distribution of the double negative thymocyte subsets as studied by the CD25 and CD44 surface antigen expression (Fig   1) . Together, these data demonstrate that thymus reconstitution, following ex-vivo retroviral gene transfer is directly dependent on the recipients' irradiation dose. The spleen, lymph nodes and bone marrow cell counts were similar in all groups i.e. RAG1-TM (3 or 8 Gy irradiated), WT-CTRL and wild-type C57BL/10 mice (Table 1) . However, the proportion of mature B lymphocytes (B220
was reduced in the lymphoid organs of RAG1-TM mice when compared to both control groups. Such a difference was not observed in the mature T cell compartment (Fig 2) . In all the RAG1-TM mice, circulating mature T cells became detectable 6 weeks after gene therapy with a slight steady increase during the first 4 months of reconstitution. T cell counts and CD4/CD8 ratio reached WT-CTRL levels within 6 months and remained stable up to one-year post gene therapy (Fig 3a, 3c ). These cell counts were very similar to those detected in age-matched wild type C57BL/10 mice attesting that only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From the T cell peripheral pool was fully reconstituted. In contrast, blood B lymphocyte reconstitution was delayed in RAG1-TM mice and B cell counts remained persistently lower than in control mice (Fig 3b, 3c) . Of note, B cell counts in WT-CTRL mice were lower than in age-matched wild-type C57BL/10 mice (1883±372 and 4300±809 cells/mm 3 , respectively) even one year after gene therapy. Unlike the differences observed between thymic reconstitution in the 3Gy and 8Gy recipients mice, cell counts and lymphocyte subset distribution were similar in the lymphoid organs and in the peripheral blood of both irradiated recipient groups.
T and B cell characteristics after gene therapy
To analyze the Vβ and Vα diversity of the TCR, immunoscope studies were performed on splenocytes, 6 months after transplantation. No significative differences were observed between RAG1-TM and WT-CTRL mice (Fig 4a, 4b) Fig 4d) . Total IgG and IgM serum immunoglobulin levels were found to be equivalent in RAG1-TM and WT-CTRL mice (Fig 4e) . Moreover, following immunization with the T-dependent antigen KLH, newly generated B cells were able to produce specific antibodies of both IgM and IgG isotypes at a similar extent than WT-CTRL (Fig 4f) .
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Provirus integration and expression of the hRAG-1 transgene
To quantify the integration and expression of the human RAG-1 transgene (hRAG-1), genomic DNA and RNA were prepared from primary and secondary lymphoid organs as well as from T, B and granulocytes cells sorted from splenocytes. The hRAG-1 copy number was found to be higher in lymph node cells, thymocytes and splenocytes than in the bone marrow cells of RAG1-TM mice (Fig 5a) . In addition, a direct correlation was found between the provirus copy number and thymus reconstitution as measured by DP cell counts. In fact, DP cells were not detected when 4 hRAG-1 copies/cell or less were found in thymocytes whereas the presence of 5 or more hRAG-1 copies/cell was associated with a ten-fold increase in DP cells and total thymocyte counts (Fig 5b) . These results indicate that in RAG1-TM mice, thymic reconstitution occurred only above a threshold of integrated hRAG-1 copies. In the spleen, a mean of 5 provirus copies/cell and 1.5 copies/cell was detected in lymphocytes and granulocytes, respectively (fig 5c) . The latter indicates that transduced lymphoid progenitors had a selective advantage over non-transduced cells. Interestingly, the expression of hRAG-1 transgene was higher in the thymus than in peripheral lymphoid organs (Fig 5d) . However, in the thymus, it corresponded only to a 30% magnitude as compared to mRAG-1 expression in control thymus. Conversely, hRAG-1 expression was found slightly more elevated in the bone marrow of RAG1-TM mice as compared to mRAG-1 expression in control mice. This is likely a consequence of the presence of transduced myeloid cells in the former case.
Stability of transgene expression
RAG1-TM mice were analyzed for more than 1 year after treatment. At the last time point (1 year after transplantation), the cell counts of circulating mature T and B cells were identical to those of mice studied 6 months after gene transfer, showing the stability of the immune deficiency correction over time. To determine whether stable integration of the hRAG-1
transgene was achieved in RAG-1-deficient hematopoietic stem cells, 5x10 6 BM cells from 6 month-old reconstituted RAG-1 TM mice were injected into RAG-1 -/-recipients (n=10). The mice were analyzed up to 7 months following secondary transplantation. T and B lymphocytes were detectable in all the organs (Fig 6a) , although total cell count was low compared to the one observed in primary treated mice. Immunoscope analysis demonstrated that a diverse TCR repertoire was restored (Fig 6b) . Despite low B cell reconstitution, serum immunoglobulin levels as well as specific antibody responses toward KLH were comparable to control mice (data not shown). A high provirus copy number was also found in the thymus, lymph nodes and spleen of secondary recipient mice, confirming the requirement for a high RAG-1 copy number to achieve reconstitution of T and B cell compartments (Fig 6c) . A low provirus copy number was found in the bone marrow, likely reflecting a lower proportion of transduced progenitor cells in the secondary transplanted animals.
Toxicity
Six months after gene therapy, one mouse from the 8Gy irradiated group was killed because of a rapidly arising slow-moving behaviour and weight loss. No cells were found in the thymus and lymph nodes of this animal (<1,000 cells) and conversely, the liver and spleen were enlarged. Of note, the PBL analysis performed at 6 and 16 weeks post-transplantation did not reveal any aberrant lymphocyte distribution and leukocyte counts (600 and 1,000 T lymphocytes/mm 3 ; 50 and 160 B lymphocytes/mm 3 at 6 and 16 weeks, respectively).
Hepatosplenomegaly (510x10 6 cells) was the consequence of a monomorphic infiltration of lymphocytes that did not express any tested lymphoid differentiation marker but exhibited the morphology of an undifferentiated acute leukemic proliferation (Fig 7) . Provirus integration study showed a very high copy number in the enlarged lymphoid organs (25 copies/cell in the spleen and 23 copies/cell in the liver, respectively) as well as in the bone marrow (16 only.
For It is noteworthy to stress that immunological reconstitution was only observed when a high copy number of hRAG-1 transgene per cell could be detected. A high copy number may be required in order to compensate for a low transcription rate of hRAG-1 transgene which accounted for only 30% of mRAG-1 expression in control thymus. The slightly higher hRAG-1 expression in the bone marrow of RAG1-TM mice compared to endogenous mRAG-1 expression in the same organ could be explained by the presence of both lymphoid and myeloid transduced cells. Of note, a high transgene copy number may also be required to compensate for a less active RAG-1 protein because human RAG-1 cDNA was used. All these data suggest that RAG-1 expression may need to reach a minimum threshold to achieve functionality during lymphoid development. Finally, the requirement for a high copy number A selective advantage of RAG-1 transduced cells over non transduced cells was clearly observed, as previously reported in other immunodeficient mouse models of gene therapy 9,10,11,12 as well as in two clinical trials performed for children affected with two SCID diseases (i.e. γc and ADA deficiencies) 5, 6, 7, 8 . This observation was expected despite the fact that lymphoid differentiation block caused by RAG-1 deficiency occurs at a later stage of hematopoieisis than the one caused by the γc chain or ADA deficiency. However, the selective advantage of RAG-1 transduced cells does not appear to be as strong since a high transduction rate and a cytoreductive treatment were required to achieve the correction of the immunodeficiency. These two conditions were not found to be as stringently required for correction of RAG-2 deficiency by gene therapy 11 . The discrepancy might be explained in different ways: both therapeutic genes have a different size (1,5 kb versus 3,1 kb for RAG-2 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From and RAG-1, respectively) that could influence transgene expression. The genetic background of these knock-out mice is also not identical: C57BL/6 and C57BL/10 for RAG-2 and RAG-1, respectively. As previously described, the phenotype and function of the hematopoietic stem cell could differ according to mice strain and this could have an influence on the immune reconstitution 34 .
The high copy number required to restore the RAG-1 immunodeficiency led to the occurrence first demonstrated that a single vector copy integrated into the murine Evi1 gene is enough to induce activation of this transcription factor. When multiple provirus insertion per cell is detected, the probability to activate genes able to cooperate in the oncogenetic process is only.
For One potential concern of RAG-1 gene therapy is the potential toxicity of uncontrolled RAG-1 expression driven by a continuously active promoter. Physiologically, both RAG-1 and RAG-2 proteins need to be expressed to induce a DNA double-strand break at the recombination signal sequences sites 15 and this process is highly and coordinately controlled and restricted to T and B cell precursors 41, 42, 43, 44 . Isolated RAG-1 or RAG-2 protein expression is devoid of activity on DNA and only the persistent expression of both proteins disturbs thymopoiesis as shown in double transgenic murine model 35, 45 . As indeed observed in both RAG-1 and RAG-2 gene transfer experiences in the respective RAG-1-/-and RAG-2-/-11 animals, no such toxicity has been observed. Nevertheless, RAG-1 treated animals are currently being monitored for an extended period of one year in order to detect any long term toxicity of uncontrolled RAG-1 expression.
In conclusion, we have shown that RAG-1 gene transfer can correct immunodeficiency associated with RAG-1 defect for over one year. We have also demonstrated that type C retroviral vectors are able to transduce a significant number of murine hematopoietic stem cells as shown by the data of secondary bone marrow transplantation. In this setting, the immunological reconstitution is only observed when a high provirus copy number is found and this is associated with an increased risk of toxicity. These results are reminiscent of the only.
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